Cargando…

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study

Detalles Bibliográficos
Autores principales:	Johnston, Douglas T., Busse, Paula J., Riedl, Marc A., Maurer, Marcus, Anderson, John, Nurse, Christina, Inhaber, Neil, Yu, Ming, Banerji, Aleena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290609/ https://www.ncbi.nlm.nih.gov/pubmed/34166549 http://dx.doi.org/10.1111/cea.13974

Ejemplares similares

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Optimal Management of Hereditary Angioedema: Shared Decision-Making
por: Banerji, Aleena, et al.
Publicado: (2021)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain
por: Staller, Kyle, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States
por: Riedl, Marc A, et al.
Publicado: (2018)

Analysis of icatibant for the treatment of laryngeal hereditary angioedema attacks in the FAST-3 study
por: Yang, William, et al.
Publicado: (2014)

Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema
por: Steiner, Urs C., et al.
Publicado: (2018)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
por: Bygum, Anette, et al.
Publicado: (2017)

Management of acute attacks of hereditary angioedema: role of ecallantide
por: Duffey, Hannah, et al.
Publicado: (2015)

Hereditary Angioedema Attack in Utero and Treatment of the Mother and Fetus
por: Grivcheva-Panovska, Vesna, et al.
Publicado: (2020)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012)

The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack
por: Park, Erin G, et al.
Publicado: (2022)

Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks
por: Bernstein, Jonathan A., et al.
Publicado: (2020)

Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy
por: Lumry, William, et al.
Publicado: (2020)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
por: Cohn, Danny M., et al.
Publicado: (2023)

Comparison of the Frequency of Angioedema Attack, before and during Pregnancy, in a Patient with Type I Hereditary Angioedema
por: Satomura, Atsushi, et al.
Publicado: (2017)

Leukocytosis and high hematocrit levels during abdominal attacks of hereditary angioedema
por: Ohsawa, Isao, et al.
Publicado: (2013)

Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency
por: Rubinstein, Eitan, et al.
Publicado: (2014)

Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
por: Tyson, Christopher, et al.
Publicado: (2019)

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema
por: Farkas, Henriette, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_adu0krgpr2mrrlac150aq3i3ve